

Molecular Therapeutics of Cancer Research Conference

Sponsored by the Cancer Molecular Therapeutics Research Association

Skamania Lodge – Stevenson, WA

July 17-21, 2022

Schedule and Program

IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers

****Lodging and meals will be at Skamania Lodge – Stevenson, WA on the Columbia River Gorge****

SUNDAY – JULY 17

4:00 pm	Arrival and check-in (Lobby)
6:00 – 7:00 pm	<i>Dinner</i>
7:30 – 7:45 pm	Welcome / Introductory Comments Peter Houghton, Greehey Children’s Cancer Research Institute, San Antonio, TX, President CMTRA
7:45 – 9:45 pm	KEYNOTE SPEAKER Tomas Lynch, Fred Hutchinson Cancer Research President and Director
10:00 pm onwards	<i>Opening reception</i>

MONDAY – JULY 18

7:30 – 8:15 am	<i>Breakfast</i>
8:30 – 12:00 pm	MORNING SESSION: IO Potentiation – DNA damage, small molecules, and antibodies Discussion Leader: Bob Abraham, Odyssey Therapeutics
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	“How tumors with chromosomal instability evade immune surveillance” Sam Bakhoun, Memorial Sloan Kettering Cancer Center
9:15 – 9:40 am	Discussion
9:40 – 10:00 am	Coffee Break
10:00 – 10:30 am	“Combining inhibitors of the DNA damage response with immunotherapies to treat cancer” Mark O’Connor, AstraZeneca

10:30 – 10:55 am	Discussion
11:00 – 11:30 am	“Molecular pattern recognition in response to DNA damage” Roger Greenberg, Perelman School of Medicine, University of Pennsylvania
11:30 – 11:55 am	Discussion
12:00 – 1:00 pm	<i>Lunch</i>
1:00 – 4:45 pm	OPEN NETWORKING AFTERNOON—(Activities Handout)
5:00 – 6:30 pm	Poster Session and Social
6:30 – 7:30 pm	<i>Dinner</i>
7:30 – 9:45 pm	EVENING SESSION: Selective Inhibitors of PI3Ka Oncogenic Mutants Discussion Leader: Jim Winkler, OnKure
7:30 – 7:45 pm	Introduction
7:45 – 8:15 pm	TBD, Relay Therapeutics
8:15 – 8:45 pm	Discussion
8:45 – 9:15 pm	TBD, Eli Lilly
9:15 – 9:45 pm	Discussion
9:45 pm onwards	<i>Social</i>

TUESDAY – JULY 19

7:30 – 8:15 am	<i>Breakfast</i>
8:30 – 12:00 pm	MORNING SESSION: Targeting Oncogenic KRAS Mutants Discussion Leader: Eli Wallace, BridgeBio
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	“Beyond KRAS G12C: Targeting other KRAS mutant cancers” Jamie Christensen, Mirati
9:15 – 9:40 am	Discussion
9:40 – 10:00 am	<i>Group Picture and Coffee Break</i>
10:00 – 10:30 am	“A KRAS Inhibitor at Last – Elucidating Mechanisms of Resistance and Combination

Strategies to Maximize Patient Benefit”
Angela Coxon, Amgen

10:30 – 10:55 am	Discussion
11:00 – 11:30 am	“Mechanisms of resistance to KRAS inhibition” Andrew Acuirre, Dana-Farber Cancer Institute
11:30 – 12:00 pm	Discussion
12:00 – 1:00 pm	<i>Lunch</i>
1:00 – 4:45 pm	OPEN NETWORKING AFTERNOON
5:00 – 6:30 pm	Poster Session and Social
6:30 – 7:30 pm	<i>Dinner</i>
7:30 – 9:45 pm	EVENING SESSION: New advances in ADC biology, chemistry and clinical results Discussion Leader: Phil Dennis, Sanofi
7:30 – 7:45 pm	Introduction
7:45 – 8:15 pm	TBD Puja Sapra, AstraZeneca
8:15 – 8:40 pm	Discussion
8:45 – 9:15 pm	“The Evolving Landscape of Antibody-Drug Conjugates for Targeted Therapy of Cancer” Robert Lyon, Seagen
9:15 – 9:40 pm	Discussion
9:40 pm onwards	<i>Social</i>

WEDNESDAY – JULY 20

7:30 – 8:15 am	<i>Breakfast</i>
8:30 – 12:00 pm	MORNING SESSION: Advances in the Treatment of Breast Cancer Discussion Leader: Lori Friedman, ORIC Pharmaceuticals
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	“Latest-generation ER-targeted therapeutics in breast cancer: mechanisms & mutations” Ciara Metcalfe, Genentech

9:15 – 9:40 am	Discussion
9:40 – 10:00 am	Coffee Break
10:00 – 10:30 am	“ER α is an RNA-binding protein sustaining tumor cell survival and drug resistance” Davide Ruggero, UCSF
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	“CDK4/6 inhibitors: why they work and how they fail” Sarat Chandarlapaty, MSKCC
11:30 – 11:55 am	Discussion
12:00 – 1:00 pm	<i>Lunch</i>
2:00 – 3:00 pm	ORAL PRESENTATIONS – Four Selected Presenters from the Poster Abstracts TBD
3:00 – 5:30 pm	AFTERNOON SESSION: RAF Beyond BRAF Discussion Leader: Shiva Malek, Novartis
3:00 – 3:15 pm	Introduction
3:15 – 3:45 pm	“New insights into oncogenic RAS mutants and RAS post translational modifications” Sharon Campbell, UNC
3:45 – 4:10 pm	Discussion
4:10 – 4:40 pm	TBD, Arvin Dar, Mount Sinai
4:45 – 5:10 pm	Discussion
6:00 – 10:00 pm	<i>Farewell Reception</i>

THURSDAY – JULY 21

7:30 – 8:15 am	<i>Breakfast</i>
11:00 am	Check out by 11:00 am

This meeting would not be possible without the generous contributions from our many sponsors, friends and colleagues

TBA